CX-2009
- Generic Name
- CX-2009
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2145115-85-9
- Unique Ingredient Identifier
- RD2I59M9FC
- Background
CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
Advances in ADCs: Opportunities for Treatment, Challenges, and Managing Toxicities
Antibody-drug conjugates (ADCs) are emerging in oncology, with dozens approved by the FDA. ADCs offer a 'bystander effect' but can increase off-target toxicity. Aditya Bardia highlighted ADCs like sacituzumab govitecan, trastuzumab deruxtecan, and datopotamab deruxtecan, which show superiority over chemotherapy in metastatic settings. Domenica Lorusso noted over 260 ADCs in cancer trials, calling them a 'rising star' in ovarian cancer. Toon Van Gorp emphasized TROP2 as a key target in cervical cancer. Challenges include understanding ADC resistance mechanisms and managing toxicities, necessitating multidisciplinary approaches.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath